Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy

被引:152
作者
Gajate, C [1 ]
Mollinedo, F [1 ]
机构
[1] Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain
关键词
D O I
10.1074/jbc.M411781200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
While investigating the mechanism of action of the novel antitumor drug Aplidin, we have discovered a potent and novel cell-killing mechanism that involves the formation of Fas/CD95-driven scaffolds in membrane raft clusters housing death receptors and apoptosis-related molecules. Fas, tumor necrosis factor-receptor 1, and tumor necrosis factor-related apoptosis-inducing ligand receptor 2/death receptor 5 were clustered into lipid rafts in leukemic Jurkat cells following Aplidin treatment, the presence of Fas being essential for apoptosis. Preformed membrane-bound Fas ligand (FasL) as well as downstream signaling molecules, including Fas-associated death domain-containing protein, procaspase-8, procaspase-10, c-Jun amino-terminal kinase, and Bid, were also translocated into lipid rafts, connecting death receptor extrinsic and mitochondrial intrinsic apoptotic pathways. Blocking Fas/FasL interaction partially inhibited Aplidin-induced apoptosis. Aplidin was rapidly incorporated into membrane rafts, and drug uptake was inhibited by lipid raft disruption. Actin-linking proteins ezrin, moesin, RhoA, and RhoGDI were conveyed into Fas-enriched rafts in drug-treated leukemic cells. Disruption of lipid rafts and interference with actin cytoskeleton prevented Fas clustering and apoptosis. Thus, Aplidin-induced apoptosis involves Fas activation in both a FasL-independent way and, following Fas/FasL interaction, an autocrine way through the concentration of Fas, membrane-bound FasL, and signaling molecules in membrane rafts. These data indicate a major role of actin cytoskeleton in the formation of Fas caps and highlight the crucial role of the clusters of apoptotic signaling molecule-enriched rafts in apoptosis, acting as concentrators of death receptors and downstream signaling molecules and as the linchpin from which a potent death signal is launched.
引用
收藏
页码:11641 / 11647
页数:7
相关论文
共 31 条
[1]   Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L [J].
Aragane, Y ;
Kulms, D ;
Metze, D ;
Wilkes, G ;
Pöppelmann, B ;
Luger, TA ;
Schwarz, T .
JOURNAL OF CELL BIOLOGY, 1998, 140 (01) :171-182
[2]   Effects of jasplakinolide on the kinetics of actin polymerization -: An explanation for certain in vivo observations [J].
Bubb, MR ;
Spector, I ;
Beyer, BB ;
Fosen, KM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (07) :5163-5170
[3]   A role for lipid rafts in B cell antigen receptor signaling and antigen targeting [J].
Cheng, PC ;
Dykstra, ML ;
Mitchell, RN ;
Pierce, SK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (11) :1549-1560
[4]   JNK activation is critical for Aplidin™-induced apoptosis [J].
Cuadrado, A ;
González, L ;
Suárez, Y ;
Martínez, T ;
Muñoz, A .
ONCOGENE, 2004, 23 (27) :4673-4680
[5]   Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells [J].
Delmas, D ;
Rébé, C ;
Lacour, S ;
Filomenko, R ;
Athias, A ;
Gambert, P ;
Cherkaoui-Malki, M ;
Jannin, B ;
Dubrez-Daloz, L ;
Latruffe, N ;
Solary, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41482-41490
[6]   Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells [J].
Friesen, C ;
Herr, I ;
Krammer, PH ;
Debatin, KM .
NATURE MEDICINE, 1996, 2 (05) :574-577
[7]  
Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO
[8]  
2-Z
[9]   Intracellular triggering of fas aggregation and recruitment of apoptotic molecules into fas-enriched rafts in selective tumor cell apoptosis [J].
Gajate, C ;
del Canto-Jañez, E ;
Acuña, AU ;
Amat-Guerri, F ;
Geijo, E ;
Santos-Beneit, AM ;
Veldman, RJ ;
Mollinedo, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (03) :353-365
[10]  
Gajate C, 2003, CLIN CANCER RES, V9, P1535